Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1231625.RAVKxsx7RjscJCjXnGIqDphRaGYAJ6z0dxDgHa_e6bXGo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1231625.RAVKxsx7RjscJCjXnGIqDphRaGYAJ6z0dxDgHa_e6bXGo130_assertion type Assertion NP1231625.RAVKxsx7RjscJCjXnGIqDphRaGYAJ6z0dxDgHa_e6bXGo130_head.
- NP1231625.RAVKxsx7RjscJCjXnGIqDphRaGYAJ6z0dxDgHa_e6bXGo130_assertion description "[The HER2 oncogene shows expression or amplification, or both, in approximately 15% to 20% of breast cancers and has been associated with poor prognosis and a response to trastuzumab therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1231625.RAVKxsx7RjscJCjXnGIqDphRaGYAJ6z0dxDgHa_e6bXGo130_provenance.
- NP1231625.RAVKxsx7RjscJCjXnGIqDphRaGYAJ6z0dxDgHa_e6bXGo130_assertion evidence source_evidence_literature NP1231625.RAVKxsx7RjscJCjXnGIqDphRaGYAJ6z0dxDgHa_e6bXGo130_provenance.
- NP1231625.RAVKxsx7RjscJCjXnGIqDphRaGYAJ6z0dxDgHa_e6bXGo130_assertion SIO_000772 25337277 NP1231625.RAVKxsx7RjscJCjXnGIqDphRaGYAJ6z0dxDgHa_e6bXGo130_provenance.
- NP1231625.RAVKxsx7RjscJCjXnGIqDphRaGYAJ6z0dxDgHa_e6bXGo130_assertion wasDerivedFrom befree-2016 NP1231625.RAVKxsx7RjscJCjXnGIqDphRaGYAJ6z0dxDgHa_e6bXGo130_provenance.
- NP1231625.RAVKxsx7RjscJCjXnGIqDphRaGYAJ6z0dxDgHa_e6bXGo130_assertion wasGeneratedBy ECO_0000203 NP1231625.RAVKxsx7RjscJCjXnGIqDphRaGYAJ6z0dxDgHa_e6bXGo130_provenance.